Financhill
Sell
24

MTVA Quote, Financials, Valuation and Earnings

Last price:
$2.03
Seasonality move :
16.32%
Day range:
$1.76 - $2.05
52-week range:
$1.51 - $6.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.32x
Volume:
256K
Avg. volume:
208.2K
1-year change:
-46.44%
Market cap:
$17.1M
Revenue:
--
EPS (TTM):
-$4.77

Analysts' Opinion

  • Consensus Rating
    MetaVia has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of --, MetaVia has an estimated upside of 775.42% from its current price of $1.98.
  • Price Target Downside
    According to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.98.

Fair Value

  • According to the consensus of 0 analysts, MetaVia has 775.42% upside to fair value with a price target of -- per share.

MTVA vs. S&P 500

  • Over the past 5 trading days, MetaVia has overperformed the S&P 500 by 26.54% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • MetaVia does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • MetaVia has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MetaVia reported revenues of --.

Earnings Growth

  • MetaVia has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MetaVia reported earnings per share of -$0.55.
Enterprise value:
-4.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$13.8M -$12.4M -$28.9M -$3.9M -$6.3M
EBITDA -$13.7M -$12.8M -$25.5M -$3.9M -$6.3M
Diluted EPS -$125.52 -$2.88 -$4.77 -$0.75 -$0.55
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets -- $7.8M $7.6M $26.1M $21.9M
Total Assets -- $8.1M $7.6M $26.4M $22.1M
Current Liabilities -- $1.9M $1.6M $4.7M $9.1M
Total Liabilities -- $2M $1.6M $4.9M $9.2M
Total Equity -- $6.1M $5.9M $21.6M $13M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$12.8M -$9.2M -$22.7M -$2.8M -$5.6M
Cash From Investing -$575K -$41K -$17K -$37K --
Cash From Financing $12.8M $28.7M $18.5M -- -$676K
Free Cash Flow -$12.8M -$9.3M -$22.7M -$2.9M -$5.6M
MTVA
Sector
Market Cap
$17.1M
$46.3M
Price % of 52-Week High
29.33%
46%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.64%
1-Year Price Total Return
-46.44%
-33.33%
Beta (5-Year)
-0.250
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $1.75
200-day SMA
Sell
Level $3.46
Bollinger Bands (100)
Sell
Level 2.26 - 3.48
Chaikin Money Flow
Sell
Level -182.4M
20-day SMA
Sell
Level $2.11
Relative Strength Index (RSI14)
Sell
Level 44.67
ADX Line
Sell
Level 18.02
Williams %R
Neutral
Level -52.6353
50-day SMA
Sell
Level $2.40
MACD (12, 26)
Sell
Level -0.20
25-day Aroon Oscillator
Sell
Level -64
On Balance Volume
Neutral
Level 435.6M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Stock Forecast FAQ

In the current month, MTVA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MTVA average analyst price target in the past 3 months is --.

  • Where Will MetaVia Stock Be In 1 Year?

    According to analysts, the consensus estimate is that MetaVia share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About MetaVia?

    Analysts are divided on their view about MetaVia share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MetaVia is a Sell and believe this share price will drop from its current level to --.

  • What Is MetaVia's Price Target?

    The price target for MetaVia over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is MTVA A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for MetaVia is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of MTVA?

    You can purchase shares of MetaVia via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MetaVia shares.

  • What Is The MetaVia Share Price Today?

    MetaVia was last trading at $2.03 per share. This represents the most recent stock quote for MetaVia. Yesterday, MetaVia closed at $1.98 per share.

  • How To Buy MetaVia Stock Online?

    In order to purchase MetaVia stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is It Time for Costco to Split?
Is It Time for Costco to Split?

Costco’s stock price has experienced enormous growth over the last…

Will FedEx’s Spinoff Boost Its Stock Price?
Will FedEx’s Spinoff Boost Its Stock Price?

In a pre-holiday surprise announcement, management at FedEx (NYSE:FDX) released…

Why Is Buffett Buying Verisign?
Why Is Buffett Buying Verisign?

Warren Buffett has spent 2024 stockpiling cash, even going so…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 41x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Buy
100
IPX alert for Dec 31

IperionX [IPX] is down 9.31% over the past day.

Buy
58
QMCO alert for Dec 31

Quantum [QMCO] is down 13.43% over the past day.

Buy
55
SMLR alert for Dec 31

Semler Scientific [SMLR] is down 4.39% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock